PDT Partners’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-16,846
| Closed | -$571K | – | 671 |
|
|
2022
Q4 | $571K | Sell |
16,846
-3,684
| -18% | -$178K | 0.09% | 360 |
|
|
2022
Q3 | $985K | Sell |
20,530
-34,970
| -63% | -$2.08M | 0.15% | 222 |
|
|
2022
Q2 | $3.16M | Buy |
55,500
+11,978
| +28% | +$756K | 0.28% | 76 |
|
|
2022
Q1 | $3.52M | Buy |
43,522
+35,835
| +466% | +$5.3M | 0.3% | 72 |
|
|
2021
Q4 | $1.56M | Sell |
7,687
-785
| -9% | -$170K | 0.12% | 274 |
|
|
2021
Q3 | $2.28M | Sell |
8,472
-2,792
| -25% | -$671K | 0.16% | 232 |
|
|
2021
Q2 | $2.9M | Buy |
11,264
+330
| +3% | +$91.3K | 0.19% | 224 |
|
|
2021
Q1 | $3.28M | Sell |
10,934
-1,319
| -11% | -$411K | 0.24% | 179 |
|
|
2020
Q4 | $3.13M | Buy |
12,253
+575
| +5% | +$149K | 0.21% | 200 |
|
|
2020
Q3 | $2.91M | Sell |
11,678
-727
| -6% | -$229K | 0.19% | 175 |
|
|
2020
Q2 | $4.31M | Sell |
12,405
-9,114
| -42% | -$2.84M | 0.29% | 130 |
|
|
2020
Q1 | $5.76M | Sell |
21,519
-5,299
| -20% | -$1.64M | 0.46% | 77 |
|
|
2019
Q4 | $8.68M | Sell |
26,818
-3,340
| -11% | -$969K | 0.54% | 71 |
|
|
2019
Q3 | $8.24M | Buy |
30,158
+15,120
| +101% | +$5.55M | 0.49% | 74 |
|
|
2019
Q2 | $8.03M | Buy |
+15,038
| New | +$7.54M | 0.47% | 83 |
|
|
2017
Q3 | – | Sell |
-44,300
| Closed | -$13M | – | 551 |
|
|
2017
Q2 | $13M | Buy |
44,300
+13,160
| +42% | +$3.8M | 0.52% | 46 |
|
|
2017
Q1 | $11M | Buy |
31,140
+14,727
| +90% | +$3.31M | 0.57% | 31 |
|
|
2016
Q4 | $3.02M | Buy |
16,413
+2,826
| +21% | +$575K | 0.2% | 192 |
|
|
2016
Q3 | $3.5M | Buy |
13,587
+47
| +0.3% | +$12.1K | 0.2% | 174 |
|
|
2016
Q2 | $2.89M | Hold |
13,540
| – | – | 0.23% | 164 |
|
|
2016
Q1 | $2.79M | Buy |
13,540
+4,787
| +55% | +$920K | 0.17% | 207 |
|
|
2015
Q4 | $2.21M | Buy |
+8,753
| New | +$1.8M | 0.3% | 143 |
|
|
2014
Q3 | – | Sell |
-4,387
| Closed | -$844K | – | 1494 |
|
|
2014
Q2 | $844K | Sell |
4,387
-1,950
| -31% | -$345K | 0.02% | 761 |
|
|
2014
Q1 | $1.15M | Sell |
6,337
-2,133
| -25% | -$422K | 0.03% | 633 |
|
|
2013
Q4 | $1.44M | Sell |
8,470
-14,320
| -63% | -$2.31M | 0.17% | 163 |
|
|
2013
Q3 | $3.57M | Buy |
22,790
+6,313
| +38% | +$1.17M | 0.1% | 271 |
|
|
2013
Q2 | $2.85M | Buy |
+16,477
| New | +$2.53M | 0.07% | 388 |
|
Other funds holding NKTR
PAMS
PDT Partners's NKTR Position: Q1 2023 in Review
PDT Partners sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 16,846 shares — an estimated $571K sold.
PDT Partners first reported a position in NKTR in Q2 2013 and held it in 27 quarters. The position peaked at $13M in Q2 2017. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.
- PDT Partners reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
- PDT Partners sold 16,846 Nektar Therapeutics shares in Q1 2023, an estimated $571K.
- PDT Partners first reported a position in Nektar Therapeutics in Q2 2013 and held it in 27 quarters.
- PDT Partners's Nektar Therapeutics position peaked at $13M in Q2 2017.
- 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.
Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.